Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: isolated limb perfusion Clear all
Completed Phase 1Phase 2 Interventional

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

NCT00421811
View directory record Official record
Conditions
Neoplasms
Interventions
ADH-1, melphalan
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2010 · Synced Sep 5, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Augmentation of Limb Perfusion With Contrast Ultrasound

NCT03195556
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ultrasound
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 3 Interventional

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

NCT00001296
View directory record Official record
Conditions
Melanoma
Interventions
melphalan, tumor necrosis factor, interferon-gamma, hyperthermic isolated limb perfusion
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Limb Perfusion During Junctional Tourniquet

NCT02092415
View directory record Official record
Conditions
Bleeding
Interventions
Application of a Junctional Tourniquet
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy

NCT00873782
View directory record Official record
Conditions
Muscular Dystrophies, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb-Girdle Muscular Dystrophy
Interventions
Retrograde high pressure transvenous perfusion with normal saline
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

NCT00001577
View directory record Official record
Conditions
Melanoma, Sarcoma
Interventions
double isolated limb perfusion with melphalan alone
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

EF5 in Melanoma Patients

NCT01752257
View directory record Official record
Conditions
Melanoma
Interventions
EF5 Hypoxia
Drug
Lead sponsor
Douglas Tyler
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional

BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI

NCT02601430
View directory record Official record
Conditions
Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
BOLD-MRI
Other
Lead sponsor
Zimmer Biomet
Industry
Eligibility
19 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

NCT00004250
View directory record Official record
Conditions
Melanoma (Skin), Sarcoma
Interventions
dactinomycin, isolated limb perfusion, melphalan
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 5, 2026, 2:29 PM EDT
Not listed Phase 1 Interventional

The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD

NCT05036213
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases
Interventions
BEET IT - Concentrate Beet root juice, BEET IT - Concentrate Beet root juice (nitrate depleted)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 5, 2026, 2:29 PM EDT
Withdrawn Phase 1 Interventional

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

NCT00661336
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

NCT02115243
View directory record Official record
Conditions
Unresectable Melanoma
Interventions
Ipilimumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

NCT01323517
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Melphalan and Dactinomycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma

NCT00002492
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, doxorubicin hydrochloride, isolated limb perfusion, conventional surgery, brachytherapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

NCT00565968
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, sorafenib tosylate, gene expression analysis, protein expression analysis, western blotting, pharmacological study
Drug · Genetic · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

NCT01127594
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide
Drug
Lead sponsor
Douglas Tyler
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 5, 2026, 2:29 PM EDT
Completed Phase 3 Interventional

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

NCT00003789
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma
Interventions
isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 5, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

NCT04332874
View directory record Official record
Conditions
Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Interventions
Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 5, 2026, 2:29 PM EDT
Withdrawn Not applicable Interventional

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

NCT02507076
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 5, 2026, 2:29 PM EDT